Immunotherapy is a relatively new approach in the treatment of cancer and it has had profound effects on the patients who are responsive to these treatments. Researchers have been working to find ways of making the therapy effective for more categories of patients, since the current immunotherapies don’t work for everyone.
Now a new study has found a way to make these treatments more effective by targeting more than one protein in the tumor microenvironment. The effect of this dual-targeting approach was that the antibody used managed to suppress a variety of tumor types in mice. The cancer types included colon, lung and breast tumors.
These therapeutic effects were attained when the antibody was used either alone or in combination with antibodies designed to block immune checkpoint proteins. The novel antibody was well-tolerated and safe in both the macaques and the mice used in this preclinical study.
Baomei Wang, who led the study, explains that their research suggests that using a dual-targeting approach in immunotherapy could provide a better way to enhance the immune system’s ability to fight tumors while also remodeling the tumor microenvironment.
Another big plus of this promising method is that it can make it harder for tumor cells to mutate or evolve in order to develop resistance against a given anticancer therapy. Tumors easily evolve to become resistant to therapy when the therapy targets just one protein or mechanism within the cancer. By having more than one target, it gets harder for the cancer to develop coping mechanisms against the treatment that it has been exposed to.
When it takes longer for a cancer to recur or become treatment-resistant, patients have a chance of longer survival, which is a big benefit not only for the patient but also their caregivers and family.
At the moment, there is still plenty of work to do before this antibody that targets two receptors on T-cells can be tested in human subjects. If the treatment succeeds during clinical trials, the fight against cancer will have registered a major milestone since there is a possibility of using this antibody to treat different cancers. Some existing immunotherapies are already approved for multiple cancer types, so the dual-targeting antibodies would broaden the effective range of immunotherapy.
While Wang and his team plan their next steps after this preclinical study, other teams, such as the R&D team at Calidi Biotherapeutics Inc. (NASDAQ: CLDI), are also focused on developing the next generation of immunotherapies indicated for various cancers.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
